Tags

Type your tag names separated by a space and hit enter

Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Drugs. 2016 Feb; 76(2):231-42.D

Abstract

Globally, the increasing prevalence of multidrug-resistant pathogens continues to pose major problems in healthcare systems and, at least in part, is driving an initiative to develop new antibacterials, such as ceftolozane (a cephalosporin β-lactam). Adding a β-lactamase inhibitor (e.g. tazobactam) to a β-lactam extends its spectrum of activity against β-lactamase-producing microorganisms (a key mechanism of resistance to β-lactams). Ceftolozane/tazobactam (Zerbaxa™), a β-lactam/β-lactamase inhibitor combination, is indicated for the treatment of adults with complicated intra-abdominal infections (cIAI) or complicated urinary tract infections (cUTI), including pyelonephritis. In multinational, phase 3 noninferiority trials, intravenous ceftolozane/tazobactam was an effective and generally well tolerated treatment in patients with cIAI or cUTI. In the ASPECT-cIAI trial, ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in terms of clinical cure rates at the test-of-cure (TOC) visit, with clinical cure rates in subgroup analyses consistent with those in the primary analysis. In the ASPECT-cUTI trial, ceftolozane/tazobactam was superior to levofloxacin in terms of composite cure rates (clinical cure plus microbiological eradiation) at the TOC visit. Further clinical experience should help to more definitively position ceftolozane/tazobactam in the treatment of cIAI and cUTI, including in patients with renal impairment. In the meantime, given its very good in vitro activity against extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa isolates, ceftolozane/tazobactam provides a potential alternative to currently approved antibacterials for empirical treatment of cIAI and cUTI in adults.

Authors+Show Affiliations

Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26746849

Citation

Scott, Lesley J.. "Ceftolozane/Tazobactam: a Review in Complicated Intra-Abdominal and Urinary Tract Infections." Drugs, vol. 76, no. 2, 2016, pp. 231-42.
Scott LJ. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. Drugs. 2016;76(2):231-42.
Scott, L. J. (2016). Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. Drugs, 76(2), 231-42. https://doi.org/10.1007/s40265-015-0524-5
Scott LJ. Ceftolozane/Tazobactam: a Review in Complicated Intra-Abdominal and Urinary Tract Infections. Drugs. 2016;76(2):231-42. PubMed PMID: 26746849.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. A1 - Scott,Lesley J, PY - 2016/1/10/entrez PY - 2016/1/10/pubmed PY - 2016/10/8/medline SP - 231 EP - 42 JF - Drugs JO - Drugs VL - 76 IS - 2 N2 - Globally, the increasing prevalence of multidrug-resistant pathogens continues to pose major problems in healthcare systems and, at least in part, is driving an initiative to develop new antibacterials, such as ceftolozane (a cephalosporin β-lactam). Adding a β-lactamase inhibitor (e.g. tazobactam) to a β-lactam extends its spectrum of activity against β-lactamase-producing microorganisms (a key mechanism of resistance to β-lactams). Ceftolozane/tazobactam (Zerbaxa™), a β-lactam/β-lactamase inhibitor combination, is indicated for the treatment of adults with complicated intra-abdominal infections (cIAI) or complicated urinary tract infections (cUTI), including pyelonephritis. In multinational, phase 3 noninferiority trials, intravenous ceftolozane/tazobactam was an effective and generally well tolerated treatment in patients with cIAI or cUTI. In the ASPECT-cIAI trial, ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in terms of clinical cure rates at the test-of-cure (TOC) visit, with clinical cure rates in subgroup analyses consistent with those in the primary analysis. In the ASPECT-cUTI trial, ceftolozane/tazobactam was superior to levofloxacin in terms of composite cure rates (clinical cure plus microbiological eradiation) at the TOC visit. Further clinical experience should help to more definitively position ceftolozane/tazobactam in the treatment of cIAI and cUTI, including in patients with renal impairment. In the meantime, given its very good in vitro activity against extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa isolates, ceftolozane/tazobactam provides a potential alternative to currently approved antibacterials for empirical treatment of cIAI and cUTI in adults. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/26746849/Ceftolozane/Tazobactam:_A_Review_in_Complicated_Intra_Abdominal_and_Urinary_Tract_Infections_ L2 - https://dx.doi.org/10.1007/s40265-015-0524-5 DB - PRIME DP - Unbound Medicine ER -